Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 9801902 Publication Model: Electronic Cited Medium: Internet ISSN: 1466-609X (Electronic) Linking ISSN: 13648535 NLM ISO Abbreviation: Crit Care Subsets: MEDLINE
    • Publication Information:
      Publication: London, UK : BioMed Central Ltd
      Original Publication: London : Current Science Ltd, c1997-
    • Subject Terms:
      Prognosis*; Adrenomedullin/*analysis ; Biomarkers/*analysis ; Endothelin-1/*analysis ; Shock, Septic/*metabolism ; Shock, Septic/*mortality; Adrenomedullin/blood ; Aged ; Aged, 80 and over ; Biomarkers/blood ; Cardiomyopathies/mortality ; Cohort Studies ; Endothelin-1/blood ; Female ; Humans ; Intensive Care Units/organization & administration ; Male ; Middle Aged ; Survival Analysis ; Sweden
    • Abstract:
      Background: Adrenomedullin and endothelin-1 are hormones with opposing effects on the cardiovascular system. Adrenomedullin acts as a vasodilator and seems to be important for the initiation and continuation of the hyperdynamic circulatory response in sepsis. Endothelin-1 is a vasoconstrictor and has been linked to decreased cardiac performance. Few studies have studied the relationship between adrenomedullin and endothelin-1, and morbidity and mortality in septic shock patients. High-sensitivity troponin T (hsTNT) is normally used to diagnose acute cardiac injury but is also prognostic for outcome in intensive care. We investigated the relationship between mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and myocardial injury, measured using transthoracic echocardiography and hsTNT in septic shock patients. We were also interested in the development of different biomarkers throughout the ICU stay, and how early measurements were related to mortality. Further, we assessed if a positive biomarker panel, consisting of MR-proADM, CT-proET-1, and hsTNT changed the odds for mortality.
      Methods: A cohort of 53 consecutive patients with septic shock had their levels of MR-proADM, CT-proET-1, hsTNT, and left ventricular systolic functions prospectively measured over 7 days. The relationship between day 1 levels of MR-proADM/CT-proET-1 and myocardial injury was studied. We also investigated the relationship between biomarkers and early (7-day) and later (28-day) mortality. Likelihood ratios, and pretest and posttest odds for mortality were calculated.
      Results: Levels of MR-proADM and CT-proET-1 were significantly higher among patients with myocardial injury and were correlated with left ventricular systolic dysfunction. MR-proADM and hsTNT were significantly higher among 7-day and 28-day non-survivors. CT-proET-1 was also significantly higher among 28-day but not 7-day non-survivors. A positive biomarker panel consisting of the three biomarkers increased the odds for mortality 13-fold to 20-fold.
      Conclusions: MR-proADM and CT-proET-1 are associated with myocardial injury. A biomarker panel combining MR-proADM, CT-proET-1, and hsTNT increases the odds ratio for death, and may improve currently available scoring systems in critical care.
    • References:
      Ann Surg. 1991 Mar;213(3):261-4. (PMID: 1998407)
      News Physiol Sci. 1999 Dec;14:255-259. (PMID: 11390861)
      Arch Surg. 1998 Dec;133(12):1298-304. (PMID: 9865646)
      Br J Anaesth. 2012 Aug;109(2):219-24. (PMID: 22617093)
      PLoS One. 2011;6(7):e21534. (PMID: 21760895)
      Heart. 2012 Sep;98(18):1348-53. (PMID: 22821276)
      BMC Anesthesiol. 2012 Sep 24;12:25. (PMID: 23006477)
      Intensive Care Med. 2011 Jan;37(1):77-85. (PMID: 20938765)
      Circulation. 2012 Oct 16;126(16):2020-35. (PMID: 22923432)
      Crit Care. 2011 Aug 16;15(4):R200. (PMID: 21846331)
      Intensive Care Med. 2009 Nov;35(11):1859-67. (PMID: 19662382)
      J Am Soc Echocardiogr. 2000 May;13(5):343-52. (PMID: 10804431)
      Peptides. 2001 Nov;22(11):1835-40. (PMID: 11754970)
      Crit Care. 2005;9(6):R816-24. (PMID: 16356231)
      Arch Intern Med. 2006 Dec 11-25;166(22):2446-54. (PMID: 17159009)
      Peptides. 2001 Nov;22(11):1745-52. (PMID: 11754960)
      J Am Coll Cardiol. 2007 Apr 10;49(14):1525-32. (PMID: 17418290)
      Ann Intensive Care. 2012 Mar 07;2:8. (PMID: 22397488)
      J Am Soc Echocardiogr. 2012 Sep;25(9):969-74. (PMID: 22795199)
      Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H988-96. (PMID: 17400719)
      J Hum Kinet. 2012 Jun;33:81-9. (PMID: 23487485)
      Clin Chem Lab Med. 2010 Dec;48(12):1813-20. (PMID: 20704539)
      Circ Res. 1991 Jan;68(1):269-79. (PMID: 1845855)
      Endothelium. 2007 Nov-Dec;14(6):345-51. (PMID: 18080871)
      Intensive Care Med. 2013 Feb;39(2):165-228. (PMID: 23361625)
      Intensive Care Med. 2010 Dec;36(12):2132-9. (PMID: 20845025)
      Clin Chem. 2006 Jun;52(6):1144-51. (PMID: 16627560)
      Eur J Pharmacol. 1999 Dec 15;386(2-3):235-45. (PMID: 10618475)
      BMJ. 2009 Feb 23;338:b375. (PMID: 19237405)
      Am Heart J. 2010 Oct;160(4):583-94. (PMID: 20934551)
      Indian Pediatr. 2011 Jun;48(6):471-3. (PMID: 21555796)
      Cardiovasc Res. 2004 Feb 1;61(2):227-37. (PMID: 14736539)
      Intensive Care Med Exp. 2013 Dec;1(1):22. (PMID: 26266791)
      Intensive Care Med Exp. 2013 Dec;1(1):21. (PMID: 26266790)
      J Crit Care. 2010 Jun;25(2):322-8. (PMID: 19781898)
      Circ Res. 2002 Oct 4;91(7):618-25. (PMID: 12364390)
      Crit Care Med. 2004 Mar;32(3):858-73. (PMID: 15090974)
      Eur J Echocardiogr. 2006 Jun;7(3):187-98. (PMID: 16046188)
      J Cardiovasc Pharmacol. 1998;31 Suppl 1:S541-4. (PMID: 9595537)
      J Clin Endocrinol Metab. 2000 Mar;85(3):1016-20. (PMID: 10720032)
      Intensive Care Med. 2007 Apr;33(4):703-10. (PMID: 17318497)
      J Crit Care. 2012 Jun;27(3):319.e9-15. (PMID: 21855287)
      Clin Chem. 2005 Oct;51(10):1823-9. (PMID: 16099941)
      Acta Anaesthesiol Scand. 2001 Nov;45(10):1262-70. (PMID: 11736680)
      Br J Anaesth. 2007 Dec;99(6):830-6. (PMID: 17962242)
      Clin Biochem. 2011 Mar;44(4):337-41. (PMID: 21211519)
      Clin Chem. 2010 Feb;56(2):254-61. (PMID: 19959623)
      J Am Coll Cardiol. 2011 Aug 30;58(10):1057-67. (PMID: 21867843)
      Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70. (PMID: 25712077)
      Eur J Pharmacol. 2000 Oct 27;407(1-2):1-15. (PMID: 11050285)
      Intensive Care Med. 2000 Mar;26(3):305-13. (PMID: 10823387)
      Eur J Echocardiogr. 2010 Jan;11(1):51-6. (PMID: 19910319)
      Circ Res. 1991 Aug;69(2):301-12. (PMID: 1860176)
      Am J Respir Crit Care Med. 1999 Jul;160(1):132-6. (PMID: 10390390)
      Crit Care. 2014 Apr 14;18(2):R73. (PMID: 24731244)
      Int J Mol Med. 2002 May;9(5):443-9. (PMID: 11956648)
    • Contributed Indexing:
      Keywords: Adrenomedullin; Echocardiography; Endothelin-1; High-sensitivity troponin; Likelihood ratio; Mortality; Myocardial injury; Sepsis; Shock
    • Accession Number:
      0 (Biomarkers)
      0 (Endothelin-1)
      148498-78-6 (Adrenomedullin)
    • Publication Date:
      Date Created: 20160611 Date Completed: 20171031 Latest Revision: 20181113
    • Publication Date:
      20231215
    • Accession Number:
      PMC4899903
    • Accession Number:
      10.1186/s13054-016-1361-y
    • Accession Number:
      27282767